BioCatalystWatch
RXRXWorkspace / RXRX / OverviewCompany library
RECURSION PHARMACEUTICALS, INC. logo

RECURSION PHARMACEUTICALS, INC.

RECURSION PHARMACEUTICALS, INC. (RXRX)

Website

Price
Market cap
Next catalyst2H26REC-102 · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

REC-4881

MEK1 (MAP2K1) × MEK2 (MAP2K2)

PreINDP1P2P3FilingApproved
REC-1245

RBM39

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

REC-7735

PI3Kα H1047R

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

REC-3565

MALT1

PreINDP1P2P3FilingApproved
Upcoming / outlook

REC-617

CDK7

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

REC-7735

PI3Kα H1047R

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

REC-1245

RBM39

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

REC-3565

MALT1

PreINDP1P2P3FilingApproved
Upcoming / outlook

REC-617

CDK7

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

REC-4881

MEK1 (MAP2K1) × MEK2 (MAP2K2)

PreINDP1P2P3FilingApproved

Other pipelines

REC-4881

MEK1 (MAP2K1) × MEK2 (MAP2K2)

PreINDP1P2FilingApproved
Upcoming / outlook

REC-102

ENPP1

Upcoming / outlook

  • Timing and evidence

REC-4539

LSD1 (KDM1A)

REC-4359

PreINDP1P2P3FilingApproved
REC-617

CDK7

PreINDP1P2P3FilingApproved
REC-617

CDK7

PreINDP1P2P3FilingApproved
REC-617

CDK7

PreINDP1P2P3FilingApproved
REC-617

CDK7

PreINDP1P2P3FilingApproved
REC-617

CDK7

PreINDP1P2P3FilingApproved
REC-617

CDK7

PreINDP1P2P3FilingApproved

Partner / License out

PreINDP2P3FilingApproved
Upcoming / outlook

History / paused

REC-4881

MEK1 (MAP2K1) × MEK2 (MAP2K2)

PreINDP1P2P3FilingApproved

C. difficile toxin B (TcdB) × C. difficile toxin A (TcdA)

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

RXRX PR & News

PR & News

RXRX SEC archive